{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:47:18Z","timestamp":1791920838846,"version":"4.3.4"},"reference-count":48,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,7,24]],"date-time":"2021-07-24T00:00:00Z","timestamp":1627084800000},"content-version":"am","delay-in-days":388,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.ijantimicag.2018.10.014","type":"journal-article","created":{"date-parts":[[2018,10,27]],"date-time":"2018-10-27T02:14:03Z","timestamp":1540606443000},"page":"105571","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["Drug-Drug Interactions Potential of Direct-Acting Antivirals for the treatment of Chronic Hepatitis C Virus infection"],"prefix":"10.1016","volume":"56","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9193-1120","authenticated-orcid":false,"given":"Nad\u00e8ge","family":"N\u00e9ant","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Solas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2018.10.014_bib0001","unstructured":"WHO. Hepatitis C fact sheet, http:\/\/www.who.int.gate2.inist.fr\/mediacentre\/factsheets\/fs164\/en\/; 2018 [accessed 18 June 2018]."},{"key":"10.1016\/j.ijantimicag.2018.10.014_bib0002","unstructured":"EASL recommendations on treatment of hepatitis C 2018, http:\/\/www.easl.eu\/research\/our-contributions\/clinical-practice-guidelines\/detail\/easl-recommendations-on-treatment-of-hepatitis-c-2018; 2018 [accessed 18 June 2018]."},{"key":"10.1016\/j.ijantimicag.2018.10.014_bib0003","unstructured":"AASLD. Recommendations for Testing, Managing, and Treating Hepatitis C, https:\/\/www.hcvguidelines.org\/; 2018 [accessed 1 July 2018]"},{"issue":"7","key":"10.1016\/j.ijantimicag.2018.10.014_bib0004","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1038\/nm.3248","article-title":"Understanding the hepatitis C virus life cycle paves the way for highly effective therapies","volume":"19","author":"Scheel","year":"2013","journal-title":"Nat Med"},{"key":"10.1016\/j.ijantimicag.2018.10.014_bib0005","doi-asserted-by":"crossref","first-page":"17006","DOI":"10.1038\/nrdp.2017.6","article-title":"Hepatitis C virus infection","volume":"3","author":"Manns","year":"2017","journal-title":"Nat Rev Dis Prim"},{"key":"10.1016\/j.ijantimicag.2018.10.014_bib0006","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhep.2018.07.002","article-title":"Challenges and perspectives of direct antivirals for the treatment of hepatitis C virus infection","author":"Vermehren","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.ijantimicag.2018.10.014_bib0007","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1097\/MEG.0000000000000152","article-title":"Medication use and medical comorbidity in patients with chronic hepatitis C from a US commercial claims database: high utilization of drugs with interaction potential","volume":"26","author":"Lauffenburger","year":"2014","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.ijantimicag.2018.10.014_bib0008","unstructured":"European Medicines Agency. Summary product of characteristics EPCLUSA, http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/004210\/WC500211151.pdf; 2016. [accessed 06 July 2018]"},{"issue":"4","key":"10.1016\/j.ijantimicag.2018.10.014_bib0009","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1080\/17425255.2017.1292253","article-title":"Pharmacokinetic drug evaluation of velpatasvir plus sofosbuvir for the treatment of hepatitis C virus infection","volume":"13","author":"Brieva","year":"2017","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"16","key":"10.1016\/j.ijantimicag.2018.10.014_bib0010","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1007\/s40265-016-0648-2","article-title":"Sofosbuvir\/Velpatasvir: A review in chronic hepatitis C","volume":"76","author":"Greig","year":"2016","journal-title":"Drugs"},{"key":"10.1016\/j.ijantimicag.2018.10.014_bib0011","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jhep.2016.02.044","article-title":"Pharmacokinetics, safety and efficacy of a full dose sofosbuvir-based regimen given daily in hemodialysis patients with chronic hepatitis C","volume":"65","author":"Desnoyer","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.ijantimicag.2018.10.014_bib0012","doi-asserted-by":"crossref","DOI":"10.1111\/jvh.12983","article-title":"Sofosbuvir with NS5A inhibitors in hepatitis C virus infection with severe renal insufficiency","author":"Singh","year":"2018","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.ijantimicag.2018.10.014_bib0013","doi-asserted-by":"crossref","DOI":"10.1007\/s40262-018-0645-6","article-title":"Pharmacokinetics and safety of velpatasvir and sofosbuvir\/velpatasvir in subjects with hepatic impairment","author":"Mogalian","year":"2018","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.ijantimicag.2018.10.014_bib0014","unstructured":"European Medicines Agency. Summary product of characteristics VOSEVI, http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/004350\/WC500235373.pdf; 2017 [accessed 06 July 2018]"},{"key":"10.1016\/j.ijantimicag.2018.10.014_bib0015","unstructured":"European Medicines Agency. Summary product of characteristics HARVONI, http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Assessment_Report_-_Variation\/human\/003850\/WC500234364.pdf; 2017 [accessed 06 July 2018]"},{"issue":"1","key":"10.1016\/j.ijantimicag.2018.10.014_bib0016","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1080\/17425255.2017.1255725","article-title":"Pharmacokinetics and pharmacodynamics of sofosbuvir and ledipasvir for the treatment of hepatitis C","volume":"13","author":"Cuenca-Lopez","year":"2017","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"11","key":"10.1016\/j.ijantimicag.2018.10.014_bib0017","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1007\/s40262-016-0397-0","article-title":"Clinical pharmacokinetics and pharmacodynamics of ledipasvir\/sofosbuvir, a fixed-dose combination tablet for the treatment of hepatitis C","volume":"55","author":"German","year":"2016","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"10.1016\/j.ijantimicag.2018.10.014_bib0018","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s12072-018-9859-9","article-title":"Efficacy and safety of ledipasvir\/sofosbuvir for genotype 1b chronic hepatitis C patients with moderate renal impairment","volume":"12","author":"Okubo","year":"2018","journal-title":"Hepatol Int"},{"key":"10.1016\/j.ijantimicag.2018.10.014_bib0019","unstructured":"European Medicines Agency. Summary product of characteristics MARIVET, http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/004430\/WC500233677.pdf; 2017 [accessed 06 July 2018]"},{"issue":"3","key":"10.1016\/j.ijantimicag.2018.10.014_bib0020","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01990-17","article-title":"Effects of renal impairment and hemodialysis on the pharmacokinetics and safety of the Glecaprevir and Pibrentasvir combination in hepatitis c virus-negative subjects","volume":"62","author":"Kosloski","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"issue":"15","key":"10.1016\/j.ijantimicag.2018.10.014_bib0021","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1056\/NEJMoa1704053","article-title":"Glecaprevir and Pibrentasvir in patients with HCV and severe renal impairment","volume":"377","author":"Gane","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijantimicag.2018.10.014_bib0022","unstructured":"European Medicines Agency. Summary product of characteristics ZEPATIER, http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/004126\/WC500211235.pdf; 2016 [accessed 06 July 2018]"},{"issue":"12","key":"10.1016\/j.ijantimicag.2018.10.014_bib0023","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00813-17","article-title":"Effect of hepatic impairment on the pharmacokinetics of Grazoprevir, a hepatitis C virus protease inhibitor","volume":"61","author":"Caro","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"issue":"10003","key":"10.1016\/j.ijantimicag.2018.10.014_bib0024","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1016\/S0140-6736(15)00349-9","article-title":"Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study","volume":"386","author":"Roth","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.ijantimicag.2018.10.014_bib0025","unstructured":"European Medicines Agency. Summary product of characteristics DAKLINZA http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/003768\/WC500172848.pdf; 2014 [accessed 06 July 2018]"},{"key":"10.1016\/j.ijantimicag.2018.10.014_bib0026","unstructured":"The University of Liverpool. HEP-Drug Interactions. http:\/\/www.hep-druginteractions.org [accessed 06 July 2018]."},{"key":"10.1016\/j.ijantimicag.2018.10.014_bib0027","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciy201","article-title":"Drug-drug interactions studies between hcv antivirals sofosbuvir\/velpatasvir and boosted and unboosted hiv antiretroviral regimens in healthy volunteers","author":"Mogalian","year":"2018","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.ijantimicag.2018.10.014_bib0028","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1111\/bcp.13450","article-title":"Ledipasvir and tenofovir drug interaction in human immunodeficiency virus-hepatitis C virus coinfected patients: Impact on tenofovir trough concentrations and renal safety","volume":"84","author":"Solas","year":"2018","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"10.1016\/j.ijantimicag.2018.10.014_bib0029","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1097\/QAI.0000000000000908","article-title":"Switching to tenofovir alafenamide, coformulated with elvitegravir, cobicistat, and emtricitabine, in HIV-infected patients with renal impairment: 48-week results from a single-arm, multicenter, open-label phase 3 study","volume":"71","author":"Pozniak","year":"2016","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.ijantimicag.2018.10.014_bib0030","unstructured":"Garrison K., Custodio J.M., Mccoll D., Pang P.S., Das M., Cheng F. Asia Pacific AIDS Co-infections Conference (APACC) 1-3 June 2017, Hong-Kong, Presentation 14."},{"issue":"7","key":"10.1016\/j.ijantimicag.2018.10.014_bib0031","doi-asserted-by":"crossref","first-page":"931","DOI":"10.3851\/IMP2674","article-title":"Assessment of pharmacokinetic interactions of the HCV NS5A replication complex inhibitor daclatasvir with antiretroviral agents: ritonavir-boosted atazanavir, efavirenz and tenofovir","volume":"18","author":"Bifano","year":"2013","journal-title":"Antivir Ther"},{"issue":"8","key":"10.1016\/j.ijantimicag.2018.10.014_bib0032","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1056\/NEJMoa1503153","article-title":"Daclatasvir plus sofosbuvir for HCV in patients coinfected with HIV-1","volume":"373","author":"Wyles","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijantimicag.2018.10.014_bib0033","unstructured":"US Food and Drug Administration. FDA Drug Safety Communication: FDA warns of serious slowing of the heart rate when antiarrhythmic drug amiodarone is used with hepatitis C treatments containing sofosbuvir (Harvoni) or Sovaldi in combination with another direct acting antiviral drug. http:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm439484.htm; 2015. Accessed [accessed 20 July 2018]."},{"key":"10.1016\/j.ijantimicag.2018.10.014_bib0034","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1053\/j.gastro.2015.07.051","article-title":"Extreme bradycardia after first doses of sofosbuvir and daclatasvir in patients receiving amiodarone: 2 cases including a rechallenge","volume":"149","author":"Renet","year":"2015","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.ijantimicag.2018.10.014_bib0035","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s40264-017-0586-2","article-title":"Cardiac harms of sofosbuvir: systematic review and meta-analysis","volume":"41","author":"Caldeira","year":"2018","journal-title":"Drug Saf"},{"issue":"6","key":"10.1016\/j.ijantimicag.2018.10.014_bib0036","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1053\/j.gastro.2015.09.031","article-title":"Interaction between amiodarone and sofosbuvir-based treatment for hepatitis C virus infection: potential mechanisms and lessons to be learned","volume":"149","author":"Back","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ijantimicag.2018.10.014_bib0037","article-title":"Efficacy and pharmacokinetics of glecaprevir and pibrentasvir with concurrent use of acid-reducing agents in patients with chronic HCV infection","author":"Flamm","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.ijantimicag.2018.10.014_bib0038","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1002\/hep.22044","article-title":"Herbal product use by persons enrolled in the hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) Trial","volume":"47","author":"Seeff","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.ijantimicag.2018.10.014_bib0039","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1046\/j.1365-2125.2002.01683.x","article-title":"St John's wort (Hypericum perforatum): drug interactions and clinical outcomes","volume":"54","author":"Henderson","year":"2002","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.ijantimicag.2018.10.014_bib0040","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1067\/mcp.2001.113185","article-title":"Seville orange juice-felodipine interaction: comparison with dilute grapefruit juice and involvement of furocoumarins","volume":"69","author":"Malhotra","year":"2001","journal-title":"Clin Pharmacol Ther"},{"issue":"11","key":"10.1016\/j.ijantimicag.2018.10.014_bib0041","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1016\/S0090-9556(24)15071-4","article-title":"Milk thistle, a herbal supplement, decreases the activity of CYP3A4 and uridine diphosphoglucuronosyl transferase in human hepatocyte cultures","volume":"28","author":"Venkataramanan","year":"2000","journal-title":"Drug Metab Dispos"},{"issue":"10","key":"10.1016\/j.ijantimicag.2018.10.014_bib0042","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1124\/dmd.114.057232","article-title":"The effects of milk thistle (silybum marianum) on human cytochrome P450 activity","volume":"42","author":"Kawaguchi-Suzuki","year":"2014","journal-title":"Drug Metab Dispos"},{"issue":"13","key":"10.1016\/j.ijantimicag.2018.10.014_bib0043","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1097\/QAD.0000000000000786","article-title":"Increasing use of 'party drugs' in people living with HIV on antiretrovirals: a concern for patient safety","volume":"29","author":"Bracchi","year":"2015","journal-title":"AIDS"},{"issue":"2","key":"10.1016\/j.ijantimicag.2018.10.014_bib0044","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1111\/bcp.13095","article-title":"Managing drug-drug interactions with new direct-acting antiviral agents in chronic hepatitis C","volume":"83","author":"Talavera Pons","year":"2017","journal-title":"Br J Clin Pharmacol"},{"issue":"8","key":"10.1016\/j.ijantimicag.2018.10.014_bib0045","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1124\/dmd.117.079038","article-title":"The drug-drug interaction potential of antiviral agents for the treatment of chronic hepatitis C infection","volume":"46","author":"Garrison","year":"2018","journal-title":"Drug Metab Dispos"},{"issue":"4","key":"10.1016\/j.ijantimicag.2018.10.014_bib0046","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.jhep.2012.10.027","article-title":"Clinical management of drug-drug interactions in HCV therapy: challenges and solutions","volume":"58","author":"Burger","year":"2013","journal-title":"J Hepatol"},{"issue":"5","key":"10.1016\/j.ijantimicag.2018.10.014_bib0047","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1097\/COH.0000000000000185","article-title":"Key drug-drug interactions with direct-acting antiviral in HIV-HCV coinfection","volume":"10","author":"El-Sherif","year":"2015","journal-title":"Curr Opin HIV AIDS"},{"issue":"8","key":"10.1016\/j.ijantimicag.2018.10.014_bib0048","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1080\/17425255.2017.1351942","article-title":"Drug interactions in HIV-infected patients treated for hepatitis C","volume":"13","author":"Soriano","year":"2017","journal-title":"Expert Opin Drug Metab Toxicol"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857918303066?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857918303066?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T22:06:00Z","timestamp":1775253960000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857918303066"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":48,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["S0924857918303066"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2018.10.014","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Drug-Drug Interactions Potential of Direct-Acting Antivirals for the treatment of Chronic Hepatitis C Virus infection","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2018.10.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"105571"}}